These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6503408)

  • 1. [Pharmacologic therapy of arteriosclerosis: current possibilities].
    Priego JG; Díaz Méndez M
    Med Clin (Barc); 1984 Oct; 83(10):431-2. PubMed ID: 6503408
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacologic therapy of atherosclerosis (I). Current possibilities].
    Segarra Domènech J; Santafé Oroz J
    Med Clin (Barc); 1983 Nov; 81(17):775-83. PubMed ID: 6361403
    [No Abstract]   [Full Text] [Related]  

  • 3. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lipid lowering improved? Therapeutic progress by using biological mechanisms].
    Udelhoven P
    Med Welt; 1982 Sep; 33(36):3. PubMed ID: 7132677
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
    Stratmann FW; Holler HD; Hofmann H
    Med Welt; 1981 Feb; 32(8):268-71. PubMed ID: 7207168
    [No Abstract]   [Full Text] [Related]  

  • 6. [Etofibrate lowers the atherosclerosis index].
    Mertz DP; Suermann I; Göhmann E
    Med Klin; 1981 Mar; 76(6):166-8. PubMed ID: 7231329
    [No Abstract]   [Full Text] [Related]  

  • 7. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 9. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P
    MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J; López-Delmás FJ
    Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs].
    Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Sławiński M; Czarnecka B
    Pol Tyg Lek; 1987 Dec 21-28; 42(51-52):1643-8. PubMed ID: 3330798
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of vascular insufficiency of the legs with plafibride].
    Lázaro Campillo T; Gesto Castromil R; de la Sierra L; Pujadas J; Villafana W; Moreno R
    Med Clin (Barc); 1984 Dec; 83(18):752-5. PubMed ID: 6521538
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical and therapeutic evaluation of simfibrate compared toclofibrate in atherosclerotic patients].
    De Rosa G; Savi L; De Rosa E; Pola P; Boni P
    Clin Ter; 1979 Feb; 88(3):267-79. PubMed ID: 376218
    [No Abstract]   [Full Text] [Related]  

  • 18. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 20. [Plafibride and vascular insufficiency of the lower limbs].
    Soringer Escofet FJ; Esteva de Antonio I
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.